Literature DB >> 27756099

ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori.

Hirotsugu Nagase1,2, Tomohira Takeoka1,2, Shinya Urakawa1,2, Akiko Morimoto-Okazawa1, Atsunari Kawashima1, Kota Iwahori1, Shuji Takiguchi2, Hiroyoshi Nishikawa3, Eiichi Sato4, Shimon Sakaguchi5, Masaki Mori2, Yuichiro Doki2, Hisashi Wada1.   

Abstract

Regulatory T cells (Tregs) have an immunosuppressive role in the tumor microenvironment. Since effector Tregs (eTregs), which have highly suppressive functions, are located in a subpopulation of Foxp3+ CD4+ Tregs, the TCR-inducible costimulatory receptor (ICOS) was applied as a marker of eTregs that infiltrated gastric cancer tissue and the induction pathway of ICOS+ Foxp3+ cells was analyzed by flow cytometry and immunohistochemistry. In tumor-infiltrating lymphocytes (TILs), ICOS+ Foxp3+ CD4+ T cells were abundantly observed in the late stages of gastric cancer. ICOS+ CD4+ TILs exhibited the ability to produce IL-10, but not IFN-γ, TNF, or IL-17 and also to suppress the proliferation of CFSE-labeled responder CD8+ T cells. With the agonistic ICOS-L protein (rICOS-L Ig), ICOS+ Foxp3+ cells were efficiently induced from naive CD4+ T cells under a stimulation with TGF-β and CD3/CD28 mAbs. Furthermore, when A*0201 PBMCs were cultured with the CMV or Melan-A antigenic peptide and rICOS-L Ig, the induction of CMV or Melan-A tetramer-binding CD8+ T cells, respectively, was inhibited. The expression of ICOS in Foxp3+ cells was closely related to plasmacytoid dendritic cells (pDCs) and their expression of ICOS-L and TLR9 as well as Helicobacter pylori infection. Collectively, our results demonstrate the potential of ICOS as a promising target for direct Treg-targeting therapeutic agents for gastric cancer, and that of eradicating therapy for H. pylori as an indirect immune therapy for gastric cancer.
© 2016 UICC.

Entities:  

Keywords:  Foxp3; ICOS ligand; TIL; TLR9; pDC

Mesh:

Substances:

Year:  2016        PMID: 27756099     DOI: 10.1002/ijc.30475

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

Review 1.  Mapping the genomic diaspora of gastric cancer.

Authors:  Khay Guan Yeoh; Patrick Tan
Journal:  Nat Rev Cancer       Date:  2021-10-26       Impact factor: 60.716

2.  Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.

Authors:  Kentaro Jingushi; Atsunari Kawashima; Takuro Saito; Takayuki Kanazawa; Daisuke Motooka; Tomonori Kimura; Masashi Mita; Akinaru Yamamoto; Toshihiro Uemura; Gaku Yamamichi; Koichi Okada; Eisuke Tomiyama; Yoko Koh; Makoto Matsushita; Taigo Kato; Koji Hatano; Motohide Uemura; Kazutake Tsujikawa; Hisashi Wada; Norio Nonomura
Journal:  Cancer Immunol Immunother       Date:  2022-05-22       Impact factor: 6.630

Review 3.  The immune microenvironment in gastric adenocarcinoma.

Authors:  Yana Zavros; Juanita L Merchant
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-14       Impact factor: 73.082

4.  The impact of ICOS+ regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy.

Authors:  Shinya Urakawa; Makoto Yamasaki; Tomoki Makino; Yukinori Kurokawa; Kei Yamamoto; Kumiko Goto; Miya Haruna; Michinari Hirata; Akiko Morimoto-Okazawa; Atsunari Kawashima; Kota Iwahori; Tsunekazu Mizushima; Eiichi Sato; Masaki Mori; Yuichiro Doki; Hisashi Wada
Journal:  Cancer Immunol Immunother       Date:  2020-08-16       Impact factor: 6.968

5.  Adaptive immunity profiling associated with histological subtypes and postoperative survival in gastric cancer.

Authors:  Wei Niu; Xiaxia Du; Lianyi Guo; Baohai Liu; Yanyun Wang; Meng Guo; Lili Sun
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Stage IV gastric cancer successfully treated by multidisciplinary therapy including chemotherapy, immunotherapy, and surgery: a case report.

Authors:  Makoto Kawamoto; Hideya Onishi; Norihiro Koya; Hiroyuki Konomi; Kenji Mitsugi; Risa Tanaka; Junichi Motoshita; Takashi Morisaki; Masafumi Nakamura
Journal:  Surg Case Rep       Date:  2017-10-23

7.  Increased tumor-infiltrating CD45RA-CCR7- regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress.

Authors:  Fang-Yuan Mao; Hui Kong; Yong-Liang Zhao; Liu-Sheng Peng; Weisan Chen; Jin-Yu Zhang; Ping Cheng; Ting-Ting Wang; Yi-Pin Lv; Yong-Sheng Teng; Xiao-Long Fu; Yu-Gang Liu; Xiao-Long Wu; Chuan-Jie Hao; Nan You; Ping Luo; Pei-Wu Yu; Quan-Ming Zou; Gang Guo; Yuan Zhuang
Journal:  Cell Death Dis       Date:  2017-08-17       Impact factor: 8.469

Review 8.  Emerging Functions of Regulatory T Cells in Tissue Homeostasis.

Authors:  Amit Sharma; Dipayan Rudra
Journal:  Front Immunol       Date:  2018-04-25       Impact factor: 7.561

9.  ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

Authors:  Florent Amatore; Nicolas Ortonne; Marc Lopez; Florence Orlanducci; Rémy Castellano; Saskia Ingen-Housz-Oro; Amandine De Croos; Clémentine Salvado; Laurent Gorvel; Armelle Goubard; Yves Collette; Réda Bouabdallah; Jean-Marc Schiano; Nathalie Bonnet; Jean-Jacques Grob; Philippe Gaulard; Martine Bagot; Armand Bensussan; Philippe Berbis; Daniel Olive
Journal:  Blood Adv       Date:  2020-10-27

Review 10.  Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.

Authors:  Donatella Aldinucci; Naike Casagrande
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.